ÌÇÐÄvlog

For Authors

About JAMA Ophthalmology

Neil M. Bressler, MD

Editor

• Editorial and Video Interview

JAMA Ophthalmology, published continuously since 1869, is an international, peer-reviewed ophthalmology and visual science journal. In 2019, the journal celebrates 150 years of continuous publication. JAMA Ophthalmology is a member of the ÌÇÐÄvlog, a consortium of peer-reviewed, general medical and specialty publications.

Journal Frequency and Access. JAMA Ophthalmology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 5.2 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's program.

Editorial Information. The journal’s acceptance rate is 14%. The median time to first decision is 3 days, and 36 days with review. The Journal Impact Factor is 8, the third highest ranking among ophthalmology journals. All articles are published online first. Additional information on the types of articles published and editorial policies is available in the journal's Instructions for Authors.

Editorial Team. Neil M. Bressler, MD, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, is the editor in chief. For a complete listing of the journal's Editors and Editorial Board, see Editors and Publishers.

Mission Statement. To be the indispensable source of ophthalmic knowledge for the generalist, subspecialist, and trainee; to publish innovative, clinically relevant research for the vision scientist; to be the first choice for authors to submit their important manuscripts to; and to achieve this through authoritative peer review.

JAMA Ophthalmology
ISSN 2168-6165 (Print)
ISSN 2168-6173 (Online)

Back to top

Why Publish in JAMA Ophthalmology?

JAMA Ophthalmology publishes innovative, clinically relevant research in vision science.

Impact and Reach

• Journal Impact Factor of 8, the third highest ranking among ophthalmology journals
• Broad reach through related commentary, author audio interviews, podcasts, email alerts, multimedia, and more than 48,000 social media followers (Facebook, X, LinkedIn)
• More than 5.2 million annual article views and downloads
• International authors: 68% of submissions come from outside the United States
• Extensive press coverage, with over 3,100 media mentions in 2023 and 2024 in outlets such as The Washington Post, CNN, Forbes, and Medscape
• Top Altmetric scores—JAMA Ophthalmology published 41 of the top 50 articles among ophthalmology journals, including the No. 1 article
• Number of citations, Altmetric score, page views, and PDF downloads tracked for your published article

Prompt Decisions and Rapid Publication Timelines

• Highly selective peer review and editorial evaluation, with 14% acceptance rate for all submissions
• Median time to first decision: 3 days without external peer review; 36 days with review
• Expedited peer review and online publication for select clinical trials, other major studies, or reports with urgent public health importance
• Online First publication of all articles
• Rapid publication of clinical trials, including those from the Age-Related Eye Disease Study (AREDS), AREDS2, Comparison of AMD Treatment Trials (CATT), Corneal Donor Study, Diabetic Retinopathy Clinical Research Network, Infant Aphakia Treatment Study Group, MARINA and ANCHOR investigators, Ocular Hypertension Treatment Group, Pediatric Eye Disease Investigators Group, SCORE2 Study Group, VIVID and VISTA investigators
• Coordination with meeting presentation: Opportunity to publish new research simultaneously with your presentation

Author Service

• User-friendly manuscript submission system and process
• Prompt, expert review and consideration from our experienced editors
• Highest standards followed to improve your accepted manuscript's accuracy, reliability, and readability
• CME credit available for lead authors who publish in JAMA Ophthalmology
• Opportunity for your work to be augmented with expert illustration, interactive features, video, audio, and visual abstract
• Display of content on fast, device-responsive website
• Citations, views, and Altmetric score displayed with every article
• Free public access: All research articles are freely available 12 months after publication on the journal's website
• Open access: Authors of research articles may elect to pay for immediate open access on the day of publication
• Deposit to PubMed Central: The journal deposits all published research articles into PubMed Central (PMC) for authors
• Authors may post accepted research manuscripts in public repositories on or after publication provided that they link to the published article on the journal website
• Online extras: Ability to post supplemental content online and download your article's tables and figures as PowerPoint slides
• The ÌÇÐÄvlog advantage: Authors of papers not accepted by JAMA Ophthalmology may have the option to have their papers and reviewers' comments automatically referred to one of the ÌÇÐÄvlog specialty journals and/or ÌÇÐÄvlog Open
• Authors of ophthalmology papers accepted by JAMA may have related commentaries in JAMA Ophthalmology
• Dedicated media team to promote your article to the news media and on social media

Commitment to Equity

• ÌÇÐÄvlog journals welcome manuscript submissions on equity, diversity, and inclusion (EDI).
• For more information, see the ÌÇÐÄvlog EDI Editors, Policies, and Topic Collection

For more information, see JAMA Ophthalmology Instructions for Authors. Submit your manuscript at .

Back to top

Updated November 2024